—In Israel, researchers recently examined which of several common comorbidities were more likely to occur in patients with palmoplantar plaque psoriasis. One in particular was unexpected. Plaque ...

Please provide your email address to receive an email when new articles are posted on . None of the patients with palmoplantar plaque psoriasis achieved PASI 75 or PASI 90. 37.5% of those patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with palmoplantar plaque-type psoriasis had significantly improved signs and symptoms of disease when ...

—A growing body of evidence has revealed several comorbidities associated with generalized plaque psoriasis. A new study takes a closer look at possible shared risks for a subtype, palmoplantar ...

Researchers reviewed data on 330 children and youths aged 0–18 years who had received a primary psoriasis diagnosis and who were seen at an academic pediatric dermatology clinic from 2012 to 2022.

Compared with White patients, Black male patients had a higher prevalence of palmoplantar psoriasis, according to one study. When examining risk factors associated with palmoplantar psoriasis (PP), ...

The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

Moderate to severe PPP can be effectively and safely treated with apremilast through 52 weeks, with improvement seen as early as week 2.

If you’ve struggled with itchy, irritated skin, you’ve probably sought out various creams, lotions or ointments to treat it. But if you feel like you’ve tried everything and still suffer from dry and ...